Status In progress
Decision Selected
Process TAG
ID number 3929

Provisional Schedule

Expected publication 29 July 2022

Project Team

Project lead Shonagh D'Sylva

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Novartis (alpelisib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  UK Breast Cancer Group
Comparator companies Eli Lilly (abemaciclib)
  Novartis Pharmaceuticals (ribociclib, everolimus)
  Pfizer (exemestane, palbociclib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
31 March 2022 - 21 April 2022 Draft guidance: 1
15 March 2022 Committee meeting: 1
19 November 2021 Due to operational challenges the committee meeting for Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer will be moving from 18 January 2021 to the 15 March 2021.
17 May 2021 Invitation to participate
15 March 2021 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual